Selected Publications
Women in STEM becoming independent: Our shared motivation and enthusiasm are our driving force. Andreeva L, Bosurgi L, Chong SZ, Chu C, Ge Y, Hoste E, Jurado KA, Lengefeld J, Mishra A, Wculek S, Young A. J Exp Med. 2024 Aug 5;221(8):e20240971. doi: 10.1084/jem.20240971.
Cina ML, Venegas J, Young A. Stocking the toolbox-Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events. Immunol Rev. 2023 Sep;318(1):110-137. doi: 10.1111/imr.13250. Epub 2023 Aug 10. Review. PubMed PMID: 37565407; PubMed Central PMCID: PMC10529261.
Kang JH, Bluestone JA, Young A (2021). Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol, 42(4), 293-311.
Quandt Z, Coupe C, Anderson M, Uihlein A, Young A (2020). Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus. J Endocr Soc, 4(10), bvaa114.
Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS (2021). Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Annu Rev Med, 72, 313-330.
Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA (2020). Regulatory T cell control of systemic immunity and immunotherapy response in liver Sci Immunol, 5(52).
Young A, Quandt Z, Bluestone JA (2018). The Balancing Act between Cancer Immunity and Autoimmunity in Response to Cancer Immunol Res, 6(12), 1445-1452.
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC (2018). Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Diabetes, 67(8), 1471-1480.
Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M (2018). Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Cell Rep, 23(11), 3262-3274.
Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ (2018). A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Res, 78(4), 1003-1016.
Vijayan D, Young A, Teng MWL, Smyth MJ (2017). Targeting immunosuppressive adenosine in Nat Rev Cancer, 17(12), 709-724.
Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Cancer Res, 77(17), 4684-4696.
Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ (2015). A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res, 75(18), 3800-11.
Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH (2014). RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer, 14, 808.
Young A, Mittal D, Stagg J, Smyth MJ (2014). Targeting cancer-derived adenosine: new therapeutic Cancer Discov, 4(8), 879-88.